000			04420nam a22005657a 4500
008			160308s20152015 xxu||||| |||| 00| 0 eng d
022			_a0735-1097
040			_aOvid MEDLINE(R)
099			_a26564598
245			_aCholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
251			_aJournal of the American College of Cardiology. 66(20):2201-10, 2015 Nov 17.
252			_aJ Am Coll Cardiol. 66(20):2201-10, 2015 Nov 17.
253			_aJournal of the American College of Cardiology
260			_c2015
260			_fFY2016
266			_d2016-05-24
501			_aAvailable online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
520			_aBACKGROUND: Potent cholesteryl ester transfer protein (CETP) inhibitors have been shown to substantially increase high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I levels as monotherapy and combined with statins. However, data on the effects of this class of drugs on macrophage cholesterol efflux capacity (CEC), a functional assay that characterizes a key step in the process of reverse cholesterol transport, are limited.
520			_aCONCLUSIONS: Evacetrapib, as monotherapy and combined with statins, not only increased total CEC, but also increased ABCA1-specific CEC and pre-beta-1 HDL. The mechanisms by which potent CETP inhibition increases ABCA1-specific CEC and pre-beta-1 HDL require further study. (A Study of LY2484595 in Patients With High LDL-C or Low HDL-C; NCT01105975).Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
520			_aMETHODS: We analyzed samples from 377 subjects with elevated low-density lipoprotein cholesterol (LDL-C) or low HDL-C levels who were enrolled in a phase 2 trial of evacetrapib. Percent changes from baseline in CEC (total, non-ABCA1-, and ABCA1-specific) and HDL subpopulations were evaluated after 12 weeks of treatment with placebo, statin monotherapy, evacetrapib monotherapy, or evacetrapib combined with statins. Pre-beta-1 HDL levels were quantified by immunofixation and nondenaturing 2-dimensional gel electrophoresis (2DGE).
520			_aOBJECTIVES: This study assessed the impact of evacetrapib, statins, or combination therapy on CEC.
520			_aRESULTS: Relative to placebo, evacetrapib monotherapy increased dose-dependent total and non-ABCA1-specific CEC up to 34% and 47%, respectively. Evacetrapib monotherapy also increased ABCA1-specific CEC up to 26%. Relative to statin monotherapy, evacetrapib with statins also increased total, non-ABCA1-, and ABCA1-specific CEC by 21%, 27%, and 15%, respectively. In contrast, rosuvastatin and simvastatin significantly reduced total and ABCA1-specific CEC, whereas atorvastatin had no significant effect. Consistent with ABCA1-specific CEC, evacetrapib monotherapy and evacetrapib combined with statins significantly increased pre-beta-1 HDL levels as measured by either method.
546			_aEnglish
650			_a*Anticholesteremic Agents/tu [Therapeutic Use]
650			_a*Benzodiazepines/tu [Therapeutic Use]
650			_a*Cholesterol/bl [Blood]
650			_a*Dyslipidemias/dt [Drug Therapy]
650			_a*High-Density Lipoproteins, Pre-beta/bl [Blood]
650			_a*Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
650			_aATP Binding Cassette Transporter 1/me [Metabolism]
650			_aCholesterol Ester Transfer Proteins/ai [Antagonists & Inhibitors]
650			_aCholesterol Ester Transfer Proteins/me [Metabolism]
650			_aDouble-Blind Method
650			_aDrug Therapy, Combination
650			_aDyslipidemias/bl [Blood]
650			_aFemale
650			_aHumans
650			_aHydroxymethylglutaryl-CoA Reductase Inhibitors/ad [Administration & Dosage]
650			_aMale
650			_aMiddle Aged
651			_aMedStar Health Research Institute
657			_aClinical Trial, Phase II
657			_aJournal Article
657			_aMulticenter Study
657			_aRandomized Controlled Trial
700			_aBrewer, H Bryan
790			_aAdelman SJ, Brewer HB, Kane JP, Krueger KA, Nicholls SJ, Nissen SE, Rader DJ, Ruotolo G, Wang MD
856			_uhttp://dx.doi.org/10.1016/j.jacc.2015.09.013 _zhttp://dx.doi.org/10.1016/j.jacc.2015.09.013
942			_cART _dArticle
999			_c1754 _d1754